MarketPulse

urcosimod

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

OKYO Pharma CDO Backs Pipeline With $49K Share Purchase as Phase 2b/3 Trial Looms

OKYO Pharma's Chief Development Officer purchases 30,980 shares at $1.59, signaling confidence in urcosimod as company prepares Phase 2b/3 trial launch in H1 2026.
OKYOclinical-stage biopharmaceuticalneuropathic corneal pain
GlobeNewswire Inc.GlobeNewswire Inc.··Na

OKYO Pharma's Neuropathic Eye Pain Therapy Earns ARVO 2026 Presentation Slot

OKYO Pharma's urcosimod earns ARVO 2026 presentation slot for neuropathic eye pain therapy. Phase 2a data shows pain reduction and quality-of-life improvements; Phase 2b/3 trial planned for 2026.
OKYOclinical trial resultsneuropathic corneal pain
GlobeNewswire Inc.GlobeNewswire Inc.··Okyo Pharma Limited

OKYO Pharma Prices $20M Share Offering to Fund Clinical Development

OKYO Pharma prices $20M share offering to fund clinical development of urcosimod for neuropathic corneal pain treatment, advancing Phase 2b/3 trial.
OKYOPIPRclinical developmentpublic offering